Introduction {#Sec1}
============

Sarcomas are malignancies that arise from cells of mesenchymal origin, and consequently can be found in bone, muscle, fat, cartilage and other connective tissue (<http://cancer.gov/cancertopics/cancerlibrary/what-is-cancer>). They are rare, accounting for less than 1 % of cancers in adults \[[@CR1]\], and for approximately 15--20 % of tumors in children \[[@CR2]\]. In addition these tumors are very heterogeneous with over 50 distinct histologic subtypes with a wide anatomical distribution \[[@CR2]\]. Consequently due to this heterogeneity, studies of systemic therapy are very challenging. Historically they have been divided into soft tissue sarcomas, representing the majority of cases, and malignant bone sarcomas, which make up a little over 10 % \[[@CR2]\].

Soft tissue sarcomas occur most commonly in the extremities, followed by the abdomen/pelvis and head and neck region \[[@CR3]\]. In the USA, approximately 11,000 new cases are reported each year, and close to 4000 attributed deaths occur \[[@CR4], [@CR5]\]. They arise in all age groups, but are more common with age (51.7 % \>60 years, 27.6 % 40--60 years, and 20.7 % 20--40 years), with a slight male predominance (1.1 male to 1.0 female) \[[@CR6]\]. The etiology is usually unknown, though exposures to radiation, chemicals, and longstanding lymphedema have been suggested as risk factors \[[@CR6]\]. Prognosis is most strongly correlated with histological grade \[[@CR7], [@CR8]\], and to a lesser extent with tumor size, positive surgical margins and histological subtype \[[@CR9], [@CR10]\].

Primary intrathoracic sarcomas are rare soft tissue sarcomas of the lung, pleura, and mediastinum. The most common histological subtypes are angiosarcoma, leiomyosarcoma, rhabdomyosarcoma, or a sarcomatoid variant of mesothelioma \[[@CR11]\]. The rarity of these tumors is reflected in the paucity of literature specifically examining the efficacy of various treatment modalities to guide clinical therapeutic approaches. Frequently they are studied in combination with other soft tissue sarcomas, and often are not assessed as a distinct subset or not included at all \[[@CR12]--[@CR16]\]. They are commonly treated in a similar manner to soft tissue sarcomas of the extremities, for which more established guidelines exist \[[@CR17]\].

Surgery is the primary treatment for localized intrathoracic sarcomas. The role of radiation and chemotherapy, however, is less established. Radiation therapy (RT) has been effective as an adjuvant to surgery for soft tissue sarcomas of the extremity \[[@CR16], [@CR18]\] and has been shown to reduce local recurrences with either pre- or post-surgery treatments \[[@CR19]\]. The utility of chemotherapy (CT) is less clear, with no trial demonstrating a clear survival benefit in resectable soft tissue sarcoma \[[@CR20]--[@CR23]\]. Novel chemotherapeutic agents and combinations are currently being investigated in the metastatic setting, and may prove more efficacious \[[@CR24]\]. Given the paucity of published data on the management of primary intrathoracic sarcoma, the purpose of this study was to assess the treatment and outcome of patients with intrathoracic sarcoma treated at the University of Washington, with particular attention to the effect of radiation and chemotherapy on local control and overall survival.

Research methods {#Sec2}
================

Patient selection {#Sec3}
-----------------

IRB approval was obtained to review medical charts for patients diagnosed with thoracic tumors at the University of Washington Medical Center (UWMC) from January 1990 to November 2011. Patients identified with intrathoracic sarcomas via pathology and imaging, who received surgical resection with or without adjuvant CT and RT were included in the study. Patients who received initial incomplete resections elsewhere or who presented to our institution with locally recurrent disease were included, provided there was adequate information about their initial or primary tumor treatment, respectively. Over the time period analyzed, patients were treated by an experienced multi-disciplinary team of physicians. Informed consent for treatment was obtained from all patients included in this study. Neoadjuvant/adjuvant chemotherapy was administered based on individual patient presentation with particular attention to histological subtype, tumor grade, and tumor size.

Data collection {#Sec4}
---------------

Resectable intrathoracic sarcoma was defined as a non-metastatic (stage I, II or III) primary sarcoma arising in the lung, pleura, or mediastinum. Each tumor was staged using the AJCC 7th edition staging criteria \[[@CR25]\]. Patient demographic data (sex, age at diagnosis); tumor specific data (date of diagnosis, primary site, histology, size, grade, stage); margins status (positive \<1 cm, negative \>1 cm); treatment modalities received (neo-adjuvant radiation and/or chemotherapy or adjuvant radiation and/or chemotherapy); and outcomes (date of last follow-up, date of death) were obtained by retrospective chart analysis. The size of the tumor was defined as the maximum dimension (in centimeters) determined by CT at the initial diagnosis. All tumor pathology was examined centrally at the UWMC. Grade was classified according to the FNCLCC system as either low, intermediate or high-grade based on the number of mitoses, the amount of necrosis, and cellular differentiation \[[@CR26]\].

Statistical analysis {#Sec5}
--------------------

Patients were followed from date of diagnosis to death of the patient, or end of the study period. Survival curves were plotted using the Kaplan-Meier method \[[@CR27]\]. Hazard ratios for 5-, 7-, and 10-year local control and overall survival were obtained using Cox regression models \[[@CR28]\], adjusting for tumor status (positive or negative) as a potential confounder in local control, and sarcoma stage (low or high) in overall survival. For the purposes of our analysis, "low stage" was defined as any stage I or II sarcoma, while "high stage" was defined as stage III. All analyses were conducted using R v.3.1.1 \[[@CR29]\]. Local control was defined as the period from the date of first treatment to the date of first recurrence of disease at the original treatment site. Overall survival was defined as the interval between the first treatment and most recent follow-up or death.

Results {#Sec6}
=======

Patient population characteristics {#Sec7}
----------------------------------

Thirty-five adults with non-metastatic intrathoracic sarcomas treated at the University of Washington between January 1990 and November 2011 were identified. The patient population ranged in age from 19 to 75 years at the date of diagnosis (mean 47.4 years, median 49 years). There were 14 male patients (40 %) and 21 female patients (60 %). The site of tumor origin was the mediastinum in 15 cases (42.9 %), and pleura/lung in 20 cases (57.1 %). Tumor size was determined in 34 patients (97.1 %) and ranged in dimension from 2.7 cm to 33.5 cm (mean 12.3 cm). Common histological subtypes included synovial sarcoma (28.6 %), followed by leiomyosarcoma (14.3 %) and spindle cell sarcoma (11.4 %). There were 5 tumors classified as low grade (14.3 %), 12 as intermediate (34.3 %), and 18 tumors classified as high-grade (51.4 %). Five cases were categorized as stage 1B, 3 as stage IIA, 11 as stage IIb, and 16 as stage III, per the AJCC staging system. Patient characteristics, pathology, treatment and survival status are listed in Table [1](#Tab1){ref-type="table"}.Table 1Patient characteristics, pathology, treatment, local control, and overall survivalHistologyTreatment\
modalityLocationStageGradeMarginsGenderAge\
at\
DxLocal\
controlOverall\
survival\
(months)Survival\
statusAngiosarcomaSurgery onlyMediastinumIIIHPosFemale253.34AWDCarcinosarcomaSurgery + CTPleura/LungIIIHNegMale5113.613.6DODFibrosarcomaSurgery onlyMediastinumIIbIPosFemale5319.988.3DODIntimal sarcomaSurgery + CTMediastinumIIaINegMale5560.660.6AWDLeiomyosarcomaSurgery + RTMediastinumIIaINegFemale666.56.5NEDLeiomyosarcomaSurgery + CTMediastinumIIaHNegFemale203434NEDLeiomyosarcomaSurgery + CTMediastinumIIIHPosFemale338.717.8DODLeiomyosarcomaSurgery + CTPleura/lungIIbINegFemale382222CODULeiomyosarcomaSurgery onlyPleura/LungIIIHNegFemale7253.453.4NEDLiposarcomaSurgery onlyMediastinumIbLPosFemale50105.1105.1NEDLiposarcomaSurgery onlyPleura/LungIIbIPosFemale431717NEDLiposarcomaSurgery + RTPleura/LungIIbIPosMale5899NEDMPNSTSurgery + RTPleura/LungIIIHPosFemale7023.88.6DODMPNSTSurgery + RTMediastinumIbLPosFemale518.6204.6AWDPleomorphic sarcomaSurgery + RTMediastinumIIbIPosFemale552498AWDSolitary fibrous tumorSurgery onlyPleura/LungIIbHPosFemale6016.549DODSolitary fibrous tumorSurgery + RTPleura/LungIIbINegMale603429.8DODSolitary fibrous tumorSurgery onlyMediastinumIbLPosFemale755.153AWDSolitary fibrous tumorSurgery onlyPleura/LungIbLPosMale65271.1NEDSpindle cell sarcomaSurgery + RTMediastinumIIIHPosMale4471.131.8DODSpindle cell sarcomaSurgery onlyMediastinumIIIHNegMale5131.880.6DODSpindle cell sarcomaSurgery onlyMediastinumIIIHPosMale36740.3DODSpindle cell sarcomaSurgery + RTMediastinumIbLPosFemale540.145.5AWDSynovial sarcomaSurgery + CTPleura/LungIIIHPosMale4345.5163NEDSynovial sarcomaSurgery + RT + CTPleura/LungIIIHPosFemale4716311.6CODUSynovial sarcomaSurgery + CTPleura/LungIIbINegMale3811.666.6AWDSynovial sarcomaSurgery + CTPleura/LungIIbIPosFemale3237.219.9DODSynovial sarcomaSurgery onlyMediastinumIIbINegMale213.521DODSynovial sarcomaSurgery onlyPleura/LungIIIHNegMale4716.31.6DODSynovial sarcomaSurgery onlyPleura/LungIIIHPosFemale491.678.5DODSynovial sarcomaSurgery + RT + CTPleura/LungIIIHNegFemale361142.8DODSynovial sarcomaSurgery + CTPleura/LungIIIHNegMale301621.6DODSynovial sarcomaSurgery onlyPleura/LungIIIHPosFemale4703.9DODSynovial sarcomaSurgery + RT + CTPleura/LungIIIHPosMale3212.812.8DODUndifferentiated sarcomaSurgery onlyPleura/LungIIbIPosMale653.029.2DOD*Abbreviations*: *AWD* alive with disease, *CODU* cause of death unknown, *CT* chemotherapy, *DOD* dead of disease, *H* high, *I* intermediate, *L* low, *MPNST* malignant peripheral nerve sheath tumor, *NED* alive with no evidence of disease, *Neg* negative, *Pos* positive, *RT* radiation therapy

Treatment characteristics {#Sec8}
-------------------------

Twelve patients (34.3 %) received initial treatment elsewhere, prior to presenting at the UWMC. The previous treatments were excisional biopsy or surgical resection in 8 out of 12 patients (66.7 %), and surgical resection with preoperative chemotherapy in 4 patients (33.3 %). Of the 12 previously treated patients, 1 patient (8.3 %) presented with residual disease, 2 patients (16.7 %) presented with tumor recurrence, and 9 patients (75.0 %) had an alternative presentation (e.g., uncertain margin, negative margin). All 35 patients underwent surgical resection for their tumors, and postoperative margin status was recorded in all 35 cases. Of these patients, 2 (5.8 %) were left with gross disease, 20 patients (57.1 %) had a positive (\<1 cm) margin and 13 (37.1 %) had a negative margin (≥1 cm). Fifteen patients (42.9 %) received surgery only, nine patients (25.7 %) received surgery and CT (either neo-adjuvant and/or adjuvant chemotherapy), eight patients (22.9 %) received surgery and RT (either neo-adjuvant and/or adjuvant radiation therapy), and 3 patients (8.6 %) received surgery and both CT and RT (either neo-adjuvant and/or adjuvant). The number of patients who received radiation was 11 (31.4 %) and the number of patients who received chemotherapy was 12 (34.3 %). Patients receiving chemotherapy primarily received ifosfamide and doxorubicin. One leiomyosarcoma patient also received gemcitabine and docetaxel and one of the synovial sarcoma patients received carboplatin and paclitaxel. Overall the treatment groups were similarly heterogeneous, with the exception of the three patients comprising the group that received all three treatment modalities (surgery + chemo + radiation) who were all stage III, high-grade synovial sarcoma cases.

Outcome {#Sec9}
-------

The mean patient follow-up time was 3.7 years. Disease recurrence was observed in 21 patients (61.8 %). Of these 21 patients, 12 (57.1 %) experienced local recurrence, 6 (28.6 %) experienced distant metastasis, and 3 (14.3 %) experienced both local recurrence and metastasis. The most common sites of metastases were the lung and bone (three patients each site) followed by the brain (twp patients). Patient status as of last follow-up revealed 9 patients (25.7 %) alive with no evidence of disease, 6 patients (17.1 %) alive with disease, 18 patients (51.4 %) had died of disease, and 2 patients (5.7 %) for whom the cause of death was unknown.

Local control and overall survival {#Sec10}
----------------------------------

### Survival results comparing four treatment groups {#Sec11}

To compare the effects of different treatment patterns on overall and disease-free survival, the patient population was divided into four groups based on treatments received. Group 1 received surgery only, group 2 received surgery and CT, group 3 received surgery and RT, and group 4 received surgery and both CT and RT. The survival results are displayed as Kaplan-Meier curves in Fig. [1](#Fig1){ref-type="fig"}. Cox hazard ratio models comparing these treatment groups for 5-, 7-, and 10-year local control are detailed in Table [2](#Tab2){ref-type="table"}. Hazard ratios for 5-, 7-, and 10-year overall survival are detailed in Table [3](#Tab3){ref-type="table"}. Treatment with surgery alone is the reference group.Fig. 1KM curves of overall survival and disease-free survival by 4-category treatmentTable 2Cox regression model results for local control, adjusted for margin status, by treatment pattern. *N* = 35Patient treatment patternLocal control5-year endpoint7-year endpoint10-year endpointSurgery + chemo^a^0.74 (0.21, 2.58)\
*p* = 0.640.69 (0.20, 2.36)\
*p* = 0.55^b^Surgery + RT^a^0.57 (0.15, 2.23)\
*p* = 0.420.58 (0.15, 2.27) *p* = 0.44^b^Surgery + chemo + RT^a^0.50 (0.06, 4.03)\
*p* = 0.510.41 (0.05, 3.33)\
*p* = 0.40^b^Margin status positive1.46 (0.47, 4.57)\
*p* = 0.511.20 (0.41, 3.52)\
*p* = 0.74^b^Number of events:\
chem/RT/chem + RT/Ref4/3/1/84/3/1/9^ba^Treatment with surgery only is the reference group (Ref)^b^No events recorded beyond 7 yearsNumbers presented are hazard ratios (with 95 % confidence interval), unadjusted *p* valueTable 3Cox regression model results for local control, adjusted for sarcoma stage, by treatment pattern. *N* = 35Patient treatment patternOverall survival5-year endpoint7-year endpoint10-year endpointSurgery + Chemo^a^0.61 (0.16, 2.39),\
*p* = 0.480.77 (0.23, 2.60)\
*p* = 0.670.71 (0.21, 2.38),\
*p* = 0.58Surgery + RT^a^1.03 (0.26, 4.08),\
*p* = 0.970.99 (0.25, 3.84)\
*p* = 0.980.81 (0.21, 3.08),\
*p* = 0.75Surgery + Chemo + RT^a^0.54 (0.11, 2.69),\
*p* = 0.450.42 (0.09, 2.05)\
*p* = 0.280.33 (0.07, 1.65),\
*p* = 0.18Sarcoma stage high (stage III vs. lower-stage)5.51 (1.66, 18.27),\
*p* = 0.0056.76 (2.09, 21.88),\
*p* = 0.0016.06 (1.98, 18.57),\
*p* = 0.002Number of events:\
Chem/RT/Chem + RT/Ref3/3/2/74/3/2/84/3/2/9^a^Treatment with surgery only is the reference group (Ref)Numbers presented are hazard ratios (with 95 % confidence interval), unadjusted *p* value

Hazard ratios for local control at 5 years were as follows: 0.74 (95 % CI \[0.21, 2.58\]) for CT added to surgery, 0.57 (95 % CI \[0.15, 2.23\]) for RT, and 0.50 (95 % CI \[0.06, 4.03\]) with the addition of both CT and RT. At 7 years, the ratios for local control were 0.69 (95 % CI \[0.20, 2.36\]) for CT added to surgery, 0.58 (95 % CI \[0.15, 2.27\]) for RT, and 0.41 (95 % CI \[0.05, 3.33\]) with the addition of both CT and RT. 10-year local control hazard ratios were not calculated, given no events recorded after 7 years.

Hazard ratios for overall survival at 5 years were 0.61 (95 % CI \[0.16, 2.39\]) for the addition of CT to surgery, 1.03 (95 % CI \[0.26, 4.08\]) for the addition of RT, and 0.54 (95 % CI \[0.11, 2.69\]) for the addition of both CT and RT. The 7-year hazard ratios for overall survival were 0.77 (95 % CI \[0.23, 2.60\]) for CT added to surgery, 0.99 (95 % CI \[0.25, 3.84\]) for the addition of RT, and 0.42 (95 % CI \[0.09, 2.05\]) for both CT and RT with surgery. Hazard ratios for overall survival at 10 years were 0.71 (95 % CI \[0.21, 2.38\]) for CT added to surgery, 0.81 (95 % CI \[0.21, 3.08\]) for added RT, and 0.33 (95 % CI \[0.07, 1.65\]) for the addition of both CT and RT.

### Survival results comparing radiation vs. no radiation {#Sec12}

To examine the effect of RT on local control and overall survival, the patient population was divided into two treatment groups based on whether RT was administered (RT vs no RT). The survival results are displayed as Kaplan-Meier curves in Fig. [2](#Fig2){ref-type="fig"}. Cox hazard ratio models comparing these treatment groups for 5-, 7-, and 10-year local control and overall survival are detailed in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}, respectively. The hazard ratios for local control at 5- and 7-years were 0.60 (95 % CI \[0.18, 1.97\]) and 0.59 (95 % CI \[0.18, 1.91\]), respectively, compared to surgery only. There were no reported events beyond 7 years. The hazard ratio for overall survival at 5 years was 0.90 (95 % CI \[0.31, 2.68\]), 0.71 (95 % CI \[0.25, 2.04\]) at 7 years, and 0.59 (95 % CI \[0.20, 1.71\]) at 10 years.Fig. 2KM curves of overall and disease-free survival for addition of radiation therapyTable 4Cox model results for local control by receipt of radiation therapy, adjusted for margin status. *N* = 35Patient treatment patternLocal control5-year endpoint7-year endpoint10-year endpointRT (vs. no RT)0.60 (0.18, 1.97)\
*p* = 0.400.59 (0.18, 1.91)\
*p* = 0.37^a^Margin status positive1.57 (0.52, 4.75)\
*p* = 0.421.31 (0.46, 3.72)\
*p* = 0.61^a^Number of events:\
RT/no RT4/124/13^aa^No events recorded beyond 7 yearsNumbers presented are hazard ratios (with 95 % confidence interval)Table 5Cox model results for overall survival by receipt of radiation therapy, adjusted for sarcoma stage. *N* = 35Patient Treatment PatternOverall Survival5-year endpoint7-year endpoint10-year endpointRT (vs. no RT)0.90 (0.31, 2.68)\
*p* = 0.860.71 (0.25, 2.04)\
*p* = 0.530.59 (0.20, 1.71)\
*p* = 0.33Sarcoma stage high (stage III vs. lower-stage)4.75 (1.50, 15.07)\
*p* = 0.0085.69 (1.84, 17.58)\
*p* = 0.0034.96 (1.73, 14.18)\
*p* = 0.003Number of events:\
RT/no RT5/105/125/13Numbers presented are hazard ratios (with 95 % confidence interval)

### Survival results comparing chemotherapy vs. no chemotherapy {#Sec13}

To examine the effects of CT on local control and overall survival, the patient population was likewise divided into two groups (CT received vs. no CT). The survival results are displayed as Kaplan-Meier curves in Fig. [3](#Fig3){ref-type="fig"}. Cox hazard ratio models comparing these treatment groups for 5-, 7-, and 10-year local control and 5-, 7-, and 10-year overall survival are detailed in Tables [6](#Tab6){ref-type="table"} and [7](#Tab7){ref-type="table"}. The hazard ratios for local control at 5 and 7 years were 0.78 (95 % CI \[0.26, 2.35\]) and 0.69 (95 % CI \[0.24, 2.01\]). For mortality at 5 years, the hazard ratio was 0.58 (95 % CI \[0.19, 1.74\]), 0.61 (95 % CI \[0.22, 1.70\]) at 7 years, and 0.56 (95 % CI \[0.20, 1.56\]) at 10 years.Fig. 3KM curves of overall and disease-free survival for addition of chemotherapyTable 6Cox model results for local control by receipt of chemotherapy, adjusted for margin status. *N* = 35Patient treatment patternLocal control5-year endpoint7-year endpoint10-year endpointChemo (vs. no chemo)0.78 (0.26, 2.35)\
*p* = 0.670.69 (0.24, 2.01)\
*p* = 0.49^a^Margin status positive1.27 (0.42, 3.80)\
*p* = 0.671.02 (0.37, 2.85)\
*p* = 0.97Number of events:\
Chemo/no-chemo5/115/12^aa^No events recorded beyond 7 yearsNumbers presented are hazard ratios (with 95 % confidence interval)Table 7Cox model results for overall survival by receipt of chemotherapy, adjusted for sarcoma stage. *N* = 35Patient treatment patternOverall survival5-year endpoint7-year endpoint10-year endpointChemo (vs. no chemo)0.58 (0.19, 1.74)\
*p* = 0.330.61 (0.22, 1.70)\
*p* = 0.350.56 (0.20, 1.56)\
*p* = 0.26Sarcoma stage high (stage III versus lower-stage)5.42 (1.67, 17.58)\
*p* = 0.0056.40 (2.01, 20.34)\
*p* = 0.0025.69 (1.91, 16.99)\
*p* = 0.002Number of events:\
Chemo/no-chemo5/106/116/12Numbers presented are hazard ratios (with 95 % confidence interval)

Discussion {#Sec14}
==========

Intrathoracic sarcomas are a rare subgroup of soft tissue sarcoma with poor prognosis and no established standard guidelines. Our study is the largest series of intrathoracic sarcoma treated at a single institution focused on treatment and outcomes of this rare set of neoplasms. This study highlights the variability in histology and individualization of patient treatment for this disease. Though surgery is the mainstay of therapy for localized sarcomas, recent studies indicate that the addition of (neo) adjuvant radiation and/or systemic therapy can potentially improve outcomes \[[@CR3], [@CR17], [@CR30]\]. Similar studies examining thoracic wall (rather than primary pleural or pulmonary) sarcomas found that chemotherapy, radiation, and both in combination, each had a positive impact on local control and survival as adjunctive treatments \[[@CR23], [@CR31]\]. Our results, which are the first to address prognostic variables and treatment influence on local control and overall survival in intrathoracic sarcoma, are in agreement with these earlier findings for sarcomas presenting in other locations and underscore the prognostic power of high-grade disease in survival.

Notable limitations include lack of statistical power due to limited sample size and variability in treatment over the period of the study. However, our study is the first to compare these treatment modalities for intrathoracic sarcomas and attempt quantification of their effect on local control and survival. Despite the limitations, this study will serve as a benchmark for further larger studies evaluating novel approaches in the management of intrathoracic sarcoma.

Due to the numerous histological subtypes and manifestations of intrathoracic sarcomas, a multi-disciplinary approach to their management is essential, as coordination between surgery, radiation, medical oncology, pathology and radiology will facilitate clearer classification and management strategies for these rare malignancies \[[@CR17]\]. In order to improve the outcome of patients with rare diseases, it is important that treatment is undertaken at specialist centers \[[@CR32]\]. Furthermore, international collaboration is required to assess the utility of novel therapies in such malignancies as well as identifying the underlying molecular drivers of these heterogeneous diseases.
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